Abstract:

Objective To investigate the correlation between serum transforming growth factor-β1 (TGF-β1), interleukin-17 (IL-17) and the prognosis of patients with acute pyelonephritis (AP) treated with cefotaxime sodium. Methods Totally 60 AP patients treated with cefotaxime sodium in our hospital from July 2019 to July 2021 were selected and divided into poor prognosis group and good prognosis group according to the prognosis of patients after two weeks of treatment. Patients in both groups received detection of serum TGF-β1 and IL-17 levels before treatment, and the correlation between serum TGF-β1 and IL-17 and the prognosis of AP patients treated with cefotaxime sodium was analyzed. Results Totally 60 AP patients were treated with cefotaxime sodium including 8 cases with poor prognosis (13.33%) and 52 cases with good prognosis (86.67%); Logistic regression analysis showed that high serum TGF-β1 and IL-17 levels were correlated with poor prognosis of patients (OR>1, P<0.05). Receiver operating characteristic curve (ROC curve) was drawn, and the results showed that the serum TGF-β1 and IL-17 levels predicted the prognosis of AP patients treated with cefotaxime sodium alone or in combination, with areas under curve (AUC)>0.8, which had certain prediction value, among which the joint prediction value was the highest. Conclusion The levels of serum TGF-β1 and IL-17 are closely related to the prognosis of AP patients treated with cefotaxime sodium, clinically, which may predict the prognosis of this patients.

Key words: pyelonephritis, cefotaxime sodium, transforming growth factor β1, interleukin-17, prognosis